Melatonin for Migraine

Verdict: Promising but preliminary for migraine prevention

Low-dose melatonin (typically 3 mg at bedtime) appears to modestly reduce migraine frequency in adults, but the evidence is still preliminary and it is not a first-line treatment.

B 🟡 B Preliminary Evidence Published

🔬Why this grade7-layer evidence engine

This earns a Preliminary (B) grade because the supportive signal is consistent but rests on small trials. Two meta-analyses point the same way: a 2026 review of nine RCTs (PMID 41627537, n=788) found melatonin cut headache days by about 1.5 per month and raised the responder rate (RR 1.38), and a 2020 network meta-analysis (PMID 32347977, n=4,499) ranked 3 mg melatonin best for reducing migraine frequency (MD -1.71 days; responder OR 4.19). The anchor RCT by Goncalves (PMID 27165014, n=178) showed 3 mg melatonin beat placebo (2.7 vs 1.1 fewer days, p=0.009) and matched amitriptyline with fewer side effects, echoed by a small 2024 RCT (PMID 38751874).

What holds it back from a higher grade is scale and gaps. The individual trials are small, doses and formulations are not standardized, and a pediatric RCT (PMID 37466211, n=42) was negative, though it was badly underpowered and does not overturn the adult data. Cluster-headache evidence remains too thin to judge.

Regulators and clinics stay cautious. No drug agency (FDA, EFSA, NHS, WHO) endorses melatonin for migraine; EFSA's only approved claims concern sleep onset, the FDA does not consider it GRAS, and in the UK it is prescription-only. The American Headache Society lists it among optional preventive nutraceuticals (3 mg at bedtime) but calls the evidence mixed, and the Cleveland Clinic states it should not be a first-line treatment, while Harvard notes headache itself can be a side effect.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.62
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published
Confidence
84%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.618
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Efficacy and Safety of Melatonin in Migraine Prophylaxis: A Systematic Review and Meta-Analysis of RCTs
PMID: 41627537 2026 統合分析 n = 788
Finding: Melatonin reduced headache days by ~1.5/month (p<0.01), attack duration by ~5h (p=0.02), response rate RR=1.38 (p<0.01); inferior to amitriptyline on duration/severity but better tolerability.
🟢 High quality Effect size: [object Object]
View on PubMed
Melatonin and episodic migraine: pilot network meta-analysis comparing melatonin vs pharmacotherapy
PMID: 32347977 2020 統合分析 n = 4,499
Finding: Melatonin 3mg ranked best for migraine frequency reduction (MD -1.71 days vs placebo, 95% CI -3.27 to -0.14); responder OR=4.19 (95% CI 1.46-12.00).
🟢 High quality Government Effect size: [object Object]
View on PubMed
RCT comparing melatonin 3mg, amitriptyline 25mg and placebo for migraine prevention (Goncalves)
PMID: 27165014 2016 RCT (double-blind) n = 178
Finding: Melatonin reduced migraine days by 2.7/month vs 1.1 placebo (p=0.009); comparable to amitriptyline (2.2 days, p=0.19) with better tolerability.
🟢 High quality Academic Effect size: [object Object]
View on PubMed
Effect of Melatonin on Reducing Frequency and Severity of Migraine Attacks: Double-Blind RCT
PMID: 38751874 2024 RCT (double-blind) n = 60
Finding: Melatonin reduced attack frequency (p=0.032) and duration (p=0.001); analgesic use lower (p<0.001); severity NS (p=0.126); MIDAS/PSQI improved (p<0.001).
View on PubMed
Melatonin for migraine prevention in children and adolescents: RCT after single-blind placebo lead-in
PMID: 37466211 2023 RCT (double-blind) n = 42
Finding: No superiority of melatonin over placebo (median diff 0 days, 95% CI -9 to 3); underpowered (target 210, enrolled 42) with substantial missing data.
🟠 Limited quality Effect size: [object Object]
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
no basis to conclude that melatonin is GRAS source↗
L4b EU EFSA
Supportive
melatonin and reduction of sleep onset latency source↗
L4c UK NHS
Cautious
Melatonin is available on prescription only. source↗
L4d TW TFDA / 衛福部
Against
褪黑激素產品屬藥品列管 source↗
L4e WHO
Not addressed
altered melatonin excretion source↗
L5a NIH Office of Dietary Supplements
Cautious
short-term use of melatonin supplements appears to be safe source↗
L5b Mayo Clinic
Cautious
melatonin may help ease cluster headache pain source↗
L5c Cleveland Clinic
Cautious
shouldn't be considered a first-line treatment source↗
L5d Harvard Health
Not addressed
headaches, and anxiety source↗
L5e Specialty Society (condition-mapped)
Cautious
Typical treatment is 3 milligrams of melatonin before bed source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-migraine-INT-melatonin-001 繁體中文版 →